公开(公告)号：US09867873B2

公开(公告)日：2018-01-16

申请号：US14982934

申请日：2015-12-29

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: C07K14/755 ,  A61K38/48 ,  A61K39/395 ,  C12N9/96 ,  A61K38/38 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61K47/48

CPC classification number: A61K38/4846 ,  A61K9/0019 ,  A61K38/38 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K47/643 ,  C07K14/76 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/90 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/33 ,  C12N9/644 ,  C12N9/96 ,  C12Y304/21022

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20170226189A1

公开(公告)日：2017-08-10

申请号：US15491742

申请日：2017-04-19

Applicant: Bioverativ Therapeutics Inc.

Inventor： Robert T. PETERS ,  Adam R. Mezo ,  Daniel S. Rivera ,  Alan J. Bitoni ,  Susan C. Low

IPC: C07K14/755 ,  C07K14/61 ,  C07K14/56 ,  C12N9/96 ,  C07K14/59 ,  C07K14/565 ,  C12N9/64 ,  C07K14/705 ,  C07K14/505

CPC classification number: C07K14/755 ,  A61K38/00 ,  A61K47/60 ,  A61K47/642 ,  A61K47/68 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/59 ,  C07K14/61 ,  C07K14/70503 ,  C07K14/745 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/647 ,  C12N9/96 ,  C12Y304/21021 ,  C12Y304/21022

Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

公开(公告)号：US09725496B1

公开(公告)日：2017-08-08

申请号：US15491742

申请日：2017-04-19

Applicant: Bioverativ Therapeutics Inc.

Inventor： Robert T. Peters ,  Adam R. Mezo ,  Daniel S. Rivera ,  Alan J. Bitonti ,  Susan C. Low

IPC: C07K14/715 ,  C07K14/72 ,  C07K14/475 ,  C07K14/755 ,  C07K14/705 ,  C07K14/61 ,  C07K14/56 ,  C07K14/505 ,  C07K14/59 ,  C07K14/565 ,  A61K47/48 ,  C12N9/64 ,  C12N9/96 ,  A61K38/00

CPC classification number: C07K14/755 ,  A61K38/00 ,  A61K47/60 ,  A61K47/642 ,  A61K47/68 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6813 ,  A61K47/6835 ,  C07K14/475 ,  C07K14/505 ,  C07K14/555 ,  C07K14/56 ,  C07K14/565 ,  C07K14/59 ,  C07K14/61 ,  C07K14/70503 ,  C07K14/745 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/00 ,  C07K2319/30 ,  C12N9/6437 ,  C12N9/644 ,  C12N9/647 ,  C12N9/96 ,  C12Y304/21021 ,  C12Y304/21022

Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

公开(公告)号：US09675676B2

公开(公告)日：2017-06-13

申请号：US15043445

申请日：2016-02-12

Applicant: Bioverativ Therapeutics Inc.

Inventor： Glenn Pierce ,  Samantha Truex ,  Robert T. Peters ,  Haiyan Jiang

IPC: A61K38/38 ,  A61K38/48 ,  A61K39/395 ,  C12N9/96 ,  C07K16/18 ,  C12N9/64 ,  C07K14/76 ,  A61K9/00 ,  A61K47/48

CPC classification number: A61K38/4846 ,  A61K9/0019 ,  A61K38/38 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K47/643 ,  C07K14/76 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/90 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/33 ,  C12N9/644 ,  C12N9/96 ,  C12Y304/21022

Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

公开(公告)号：US20250121036A1

公开(公告)日：2025-04-17

申请号：US18890444

申请日：2024-09-19

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Jennifer DUMONT ,  Nisha JAIN ,  Desilu GLAZEBROOK

IPC: A61K38/37 ,  A61K38/48 ,  A61P7/04 ,  A61P19/02

Abstract: The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.

公开(公告)号：US12128092B2

公开(公告)日：2024-10-29

申请号：US16995173

申请日：2020-08-17

Applicant: Bioverativ Therapeutics Inc.

Inventor： Brian M. Thome ,  Cherie Parkhurst-Lang ,  Brandon W. Leveille

IPC: A61K38/36 ,  A61K9/00 ,  A61K9/19 ,  A61K38/48 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  F26B5/06

CPC classification number: A61K38/4846 ,  A61K9/0019 ,  A61K9/19 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  C12Y304/21022 ,  F26B5/06

Abstract: The present invention provides, among other things, pre-lyophilization formulations, reconstituted formulations, and lyophilate powder compositions comprising a Factor IX (FIX) polypeptide. The present invention also provides lyophilization methods for producing lyophilate powder comprising a FIX polypeptide.

公开(公告)号：US20240141019A1

公开(公告)日：2024-05-02

申请号：US18461697

申请日：2023-09-06

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Siyuan TAN ,  Robert T. PETERS

IPC: C07K14/755 ,  C12N9/64

CPC classification number: C07K14/755 ,  C12N9/6424 ,  C07K2319/30 ,  C07K2319/31

Abstract: The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides. The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.

公开(公告)号：US20240083975A1

公开(公告)日：2024-03-14

申请号：US18358601

申请日：2023-07-25

Applicant: Bioverativ Therapeutics Inc.

Inventor： Ekta Seth CHHABRA ,  John KULMAN ,  Tongyao LIU

IPC: C07K14/755 ,  A61K38/37

CPC classification number: C07K14/755 ,  A61K38/37 ,  A61K38/00

Abstract: The present invention provides a chimeric molecule comprising a VWF protein fused to a heterologous moiety via a VWF linker. The invention provides an efficient VWF linker that can be cleaved in the presence of thrombin. The chimeric molecule can further comprise a polypeptide chain comprising a FVIII protein and a second heterologous moiety, wherein the chain comprising the VWF protein and the chain comprising the FVIII protein are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins.

公开(公告)号：US11787851B2

公开(公告)日：2023-10-17

申请号：US16452010

申请日：2019-06-25

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Siyuan Tan ,  Robert T. Peters

IPC: C07K14/755 ,  C12N9/64

CPC classification number: C07K14/755 ,  C12N9/6424 ,  C07K2319/30 ,  C07K2319/31

Abstract: The present invention provides codon optimized Factor VIII sequences, vectors and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.
The present invention also provides methods of treating bleeding disorders such as hemophilia comprising administering to the subject a codon optimized Factor VIII nucleic acid sequence or the polypeptide encoded thereby.

公开(公告)号：US11685771B2

公开(公告)日：2023-06-27

申请号：US16516816

申请日：2019-07-19

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： John Kulman

IPC: C07K14/755 ,  C07K14/59 ,  C07K14/79 ,  A61K38/37 ,  A61K35/14 ,  C07K14/00 ,  C07K14/435 ,  C07K14/705 ,  C07K14/76 ,  A61K38/00

CPC classification number: C07K14/755 ,  A61K35/14 ,  A61K38/37 ,  C07K14/00 ,  C07K14/43504 ,  C07K14/59 ,  C07K14/705 ,  C07K14/76 ,  C07K14/79 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/60 ,  Y02A50/30

Abstract: Provided are recombinant Factor VIII proteins, e.g., human Factor VIII proteins with heterologous moieties inserted into flexible permissive loops located in the Factor VIII A domains, while retaining the procoagulant activity of Factor VIII.